Source:http://linkedlifedata.com/resource/pubmed/id/14506018
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2003-9-24
|
pubmed:abstractText |
The objective of the present study was to compare the activities of a third-line regimen recommended by the World Health Organization (WHO) and two derivatives of that regimen with the activity of the standard combination of isoniazid, rifampin, and pyrazinamide as a positive control against Mycobacterium tuberculosis in a murine model. The WHO regimen combines ofloxacin (OFX), ethionamide, amikacin, and pyrazinamide; in the two derivatives of this regimen, OFX was replaced by levofloxacin (LVX) or moxifloxacin (MXF). The four drugs, a fluoroquinolone (either OFX, LVX, or MXF), ethionamide, pyrazinamide, and amikacin, were administered for the first 2 months (initial phase); and two drugs, a fluoroquinolone (either OFX, LVX, or MXF) and ethionamide, were administered for the following 10 months (continuation phase). After 6 months of treatment, only the spleens and lungs of mice treated with the standard regimen became culture negative. From 9 months onward, all of the organs of mice treated with the MXF-containing third-line regimen were culture negative. The majority of organs from mice treated with the OFX-containing regimen continued to be culture positive, and the mean CFU counts remained unchanged for as long as 12 months. The results for mice treated with the LVX-containing regimen fell between those for the groups receiving the MXF- and OFX-containing regimens. In conclusion, the activity of the OFX-containing third-line regimen against M. tuberculosis was rather weak in vivo, whereas when OFX was replaced by MXF, 9 months of treatment with a modified third-line regimen displayed bactericidal activity comparable to that of 6 months of treatment with the standard regimen in mice. The MXF-containing third-line regimen seems to be a powerful alternative for the treatment of tuberculosis (TB) when isoniazid and rifampin cannot be used, which is the main feature of multidrug-resistant TB.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-10985648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-11320389,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-11709328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-11897584,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-12019103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-12543673,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-1909062,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-2817579,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-7574527,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-8031045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-8035042,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-9056001,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-9687408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-9687411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-9869570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14506018-9883616
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0066-4804
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3117-22
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:14506018-Animals,
pubmed-meshheading:14506018-Antitubercular Agents,
pubmed-meshheading:14506018-Female,
pubmed-meshheading:14506018-Fluoroquinolones,
pubmed-meshheading:14506018-Lung,
pubmed-meshheading:14506018-Mice,
pubmed-meshheading:14506018-Mycobacterium tuberculosis,
pubmed-meshheading:14506018-Organ Size,
pubmed-meshheading:14506018-Spleen,
pubmed-meshheading:14506018-Tuberculosis, Multidrug-Resistant
|
pubmed:year |
2003
|
pubmed:articleTitle |
Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.
|
pubmed:affiliation |
Laboratoire de Bactériologie, Faculté de Médecine Pitié-Salpêtrière, and Centre National de Référence de la Résistance des Mycobactéries aux Antituberculeux, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|